Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
Powles, Thomas (University of London. Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust, Queen Mary)
Motzer, Robert J. (Memorial Sloan Kettering Cancer Center)
Escudier, Bernard (Gustave Roussy)
Pal, Sumanta (City of Hope National Medical Center)
Kollmannsberger, Christian (BCCA Vancouver Cancer Centre. British Columbia Cancer Agency)
Pikiel, Joanna (Wojewodzkie Centrum Onkologii, 80-219 Gdańsk, Poland)
Gurney, Howard (Macquarie University. Macquarie University and Westmead Hospital)
Rha, Sun Young (Yonsei Cancer Center. Severance Hospital)
Park, Se Hoon (Samsung Medical Center)
Geertsen, Poul F. (Copenhagen University Hospital)
Gross-Goupil, Marine (Groupe Hospitalier Saint André, 33000 Bordeaux, France)
Grande, Enrique (Hospital Universitario Ramón y Cajal (Madrid))
Suárez, Cristina (Vall d'Hebron Institut d'Oncologia)
Markby, David W. (Exelixis, Inc)
Arroyo, Alan (Exelixis, Inc)
Dean, Mark (Exelixis, Inc)
Choueiri, Toni K. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica))
George, Daniel (Duke University Medical Center)
Universitat Autònoma de Barcelona

Fecha:	2018
Resumen:	In the phase 3 METEOR trial, cabozantinib improved progression-free survival (PFS), objective response rate (ORR), and overall survival (OS) versus everolimus in patients with advanced renal cell carcinoma (RCC), after prior antiangiogenic therapy. Outcomes were evaluated for subgroups defined by prior therapy with sunitinib or pazopanib as the only prior VEGFR inhibitor, or prior anti-PD-1/PD-L1 therapy. For the prior sunitinib subgroup (N = 267), median PFS for cabozantinib versus everolimus was 9. 1 versus 3. 7 months (HR 0. 43, 95% CI 0. 32-0. 59), ORR was 16% versus 3%, and median OS was 21. 4 versus 16. 5 months (HR 0. 66, 95% CI 0. 47-0. 93). For the prior pazopanib subgroup (N = 171), median PFS for cabozantinib versus everolimus was 7. 4 versus 5. 1 months (HR 0. 67, 95% CI 0. 45-0. 99), ORR was 19% versus 4%, and median OS was 22. 0 versus 17. 5 months (HR 0. 66, 95% CI 0. 42-1. 04). For prior anti-PD-1/PD-L1 therapy (N = 32), median PFS was not reached for cabozantinib versus 4. 1 months for everolimus (HR 0. 22, 95% CI 0. 07-0. 65), ORR was 22% versus 0%, and median OS was not reached versus 16. 3 months (HR 0. 56, 95% CI 0. 21-1. 52). Cabozantinib was associated with improved clinical outcomes versus everolimus in patients with advanced RCC, irrespective of prior therapy, including checkpoint inhibitor therapy.
Nota:	Altres ajuts: We thank the patients, their families, the investigators and site staff, and the study teams who participated in the METEOR trial. This study was funded by Exelixis, Inc. Patients treated at Memorial Sloan Kettering Cancer Center were supported in part by Memorial Sloan Kettering Cancer Center Support Grant/Core Grant (P30 CA008748). Editorial support was provided by Fishawack Communications (Conshohocken, PA, USA) and funded by Exelixis.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Publicado en:	British journal of cancer, Vol. 119 (september 2018) , p. 663-669, ISSN 1532-1827

DOI: 10.1038/s41416-018-0164-0
PMID: 30197417

7 p, 549.5 KB

El registro aparece en las colecciones:
Artículos > Artículos de investigación
Artículos > Artículos publicados